Tags

Type your tag names separated by a space and hit enter

(-)-Epigallocatechin-3-gallate modulates spinal cord neuronal degeneration by enhancing growth-associated protein 43, B-cell lymphoma 2, and decreasing B-cell lymphoma 2-associated x protein expression after sciatic nerve crush injury.
J Neurotrauma 2015; 32(3):170-84JN

Abstract

Our previous studies have established that (-)-epigallocatechin-3-gallate (EGCG) has both neuroprotective and -regenerative capacity after sciatic nerve injury. Moreover, this improvement was evident on the behavioral level. The aim of this study was to investigate the central effects of ECGC on spinal cord motor neurons after sciatic nerve injury. Our study showed that administering 50 mg/kg intraperitoneally i.p. of EGCG to sciatic nerve-injured rats improved their performance on different motor functions and mechanical hyperesthesia neurobehavioral tests. Histological analysis of spinal cords of EGCG-treated sciatic nerve-injured (CRUSH+ECGC) animals showed an increase in the number of neurons in the anterior horn, when compared to the naïve, sham, and saline-treated sciatic nerve-injured (CRUSH) control groups. Additionally, immunohistochemical study of spinal cord sections revealed that EGCG reduced the expression of glial fibrillary acidic protein and increased the expression of growth-associated protein 43, a marker of regenerating axons. Finally, EGCG reduced the ratio of B-cell lymphoma 2 (Bcl-2)-associated X protein/Bcl-2 and increased the expression of survivin gene. This study may shed some light on the future clinical use of EGCG and its constituents in the treatment of peripheral nerve injury.

Authors+Show Affiliations

1 Department of Anatomy, Faculty of Medicine, Kuwait University , Safat, Kuwait .No affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

25025489

Citation

Renno, Waleed M., et al. "(-)-Epigallocatechin-3-gallate Modulates Spinal Cord Neuronal Degeneration By Enhancing Growth-associated Protein 43, B-cell Lymphoma 2, and Decreasing B-cell Lymphoma 2-associated X Protein Expression After Sciatic Nerve Crush Injury." Journal of Neurotrauma, vol. 32, no. 3, 2015, pp. 170-84.
Renno WM, Al-Maghrebi M, Rao MS, et al. (-)-Epigallocatechin-3-gallate modulates spinal cord neuronal degeneration by enhancing growth-associated protein 43, B-cell lymphoma 2, and decreasing B-cell lymphoma 2-associated x protein expression after sciatic nerve crush injury. J Neurotrauma. 2015;32(3):170-84.
Renno, W. M., Al-Maghrebi, M., Rao, M. S., & Khraishah, H. (2015). (-)-Epigallocatechin-3-gallate modulates spinal cord neuronal degeneration by enhancing growth-associated protein 43, B-cell lymphoma 2, and decreasing B-cell lymphoma 2-associated x protein expression after sciatic nerve crush injury. Journal of Neurotrauma, 32(3), pp. 170-84. doi:10.1089/neu.2014.3491.
Renno WM, et al. (-)-Epigallocatechin-3-gallate Modulates Spinal Cord Neuronal Degeneration By Enhancing Growth-associated Protein 43, B-cell Lymphoma 2, and Decreasing B-cell Lymphoma 2-associated X Protein Expression After Sciatic Nerve Crush Injury. J Neurotrauma. 2015 Feb 1;32(3):170-84. PubMed PMID: 25025489.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - (-)-Epigallocatechin-3-gallate modulates spinal cord neuronal degeneration by enhancing growth-associated protein 43, B-cell lymphoma 2, and decreasing B-cell lymphoma 2-associated x protein expression after sciatic nerve crush injury. AU - Renno,Waleed M, AU - Al-Maghrebi,May, AU - Rao,Muddanna S, AU - Khraishah,Haitham, Y1 - 2014/11/10/ PY - 2014/7/16/entrez PY - 2014/7/16/pubmed PY - 2015/9/15/medline KW - apoptosis KW - green tea KW - neuroprotection KW - neuroregeneration KW - surviving SP - 170 EP - 84 JF - Journal of neurotrauma JO - J. Neurotrauma VL - 32 IS - 3 N2 - Our previous studies have established that (-)-epigallocatechin-3-gallate (EGCG) has both neuroprotective and -regenerative capacity after sciatic nerve injury. Moreover, this improvement was evident on the behavioral level. The aim of this study was to investigate the central effects of ECGC on spinal cord motor neurons after sciatic nerve injury. Our study showed that administering 50 mg/kg intraperitoneally i.p. of EGCG to sciatic nerve-injured rats improved their performance on different motor functions and mechanical hyperesthesia neurobehavioral tests. Histological analysis of spinal cords of EGCG-treated sciatic nerve-injured (CRUSH+ECGC) animals showed an increase in the number of neurons in the anterior horn, when compared to the naïve, sham, and saline-treated sciatic nerve-injured (CRUSH) control groups. Additionally, immunohistochemical study of spinal cord sections revealed that EGCG reduced the expression of glial fibrillary acidic protein and increased the expression of growth-associated protein 43, a marker of regenerating axons. Finally, EGCG reduced the ratio of B-cell lymphoma 2 (Bcl-2)-associated X protein/Bcl-2 and increased the expression of survivin gene. This study may shed some light on the future clinical use of EGCG and its constituents in the treatment of peripheral nerve injury. SN - 1557-9042 UR - https://www.unboundmedicine.com/medline/citation/25025489/____Epigallocatechin_3_gallate_modulates_spinal_cord_neuronal_degeneration_by_enhancing_growth_associated_protein_43_B_cell_lymphoma_2_and_decreasing_B_cell_lymphoma_2_associated_x_protein_expression_after_sciatic_nerve_crush_injury_ L2 - https://www.liebertpub.com/doi/full/10.1089/neu.2014.3491?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub=pubmed DB - PRIME DP - Unbound Medicine ER -